Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study
Nobuki Furubayashi, Jiro Tsujita, Azusa Takayama, Yuta Shiraishi, Motonobu Nakamura, Takahito Negishi · 2026
Read Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study by Nobuki Furubayashi, Jiro Tsujita, Azusa Takayama, Yuta Shiraishi, Motonobu Nakamura, Takahito Negishi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13250907.txt.
Description
Furubayashi and colleagues ask whether early growth on a two-drug immune therapy spells trouble for kidney cancer patients. Their 2026 Research and Reports in Urology study reviews Japanese patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab at one cancer center since 2018. Early progression meant growth within twelve weeks or at the first scan.
Among thirty-eight patients reaching the twelve-week mark, the fourteen with early progression lived far shorter lives than the rest. Early progression and a poor-risk score each independently predicted worse survival. Tumors that were not the common clear-cell type were much likelier to progress early. The authors suggest watching tumor type closely when choosing first-line treatment and counseling patients.
Catalog record
| CREATOR | Nobuki Furubayashi, Jiro Tsujita, Azusa Takayama, Yuta Shiraishi, Motonobu Nakamura, Takahito Negishi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |